🏆 A proud moment for the entire Aceso Therapeutics team: ACT-101 has been selected as a winner of the 2026 i-Lab Innovation Competition (28th edition), supported by Bpifrance under the France 2030 initiative! 🎉
is a leading French innovation award recognizing high-potential deep-tech startups. For a biotech, being an i-Lab laureate represents a strong validation of the scientific innovation, provides non-dilutive funding, and enhances credibility with investors and strategic partners while accelerating development toward clinical milestones.
💫 A huge thank you to the team led by Thomas Tran (CEO), alongside Magali Taulan-Cadars, Prisca Boisguerin, and the project leader Sébastien Cagnol, as well as to our supporters across the Occitanie region and everyone who has supported us throughout this journey.
📅 More to come this autumn, following the official award ceremony. 🧬